We are profiling a large cohort of CMML patients (n=157) with regard to DNA methylome, RNA seq in sorted cell populations, and 10x sequencing data in sorted specific cell populations from a smaller number of patients. The aim is to correlate DNA methylation patterns and transcriptome of the patients and fuse with our already obtained target seq mutational data, to understand more about the biology and risk factors in the rare hematological disease CMML.